Valeritas’ V-Go wins preferred status on Humana’s Medicare formularies

Valeritas (NSDQ:VLRX) said today that its V-Go insulin delivery device won preferred status on Humana’s Part D formularies.

The Bridgewater, N.J.-based company’s device is designed for people with Type 2 diabetes. Worn like a patch, the V-Go product delivers a continuous preset basal rate of insulin over 24 hours and can also provide on-demand bolus dosing at meals.

Get the full story at our sister site, Drug Delivery Business News.

The post Valeritas’ V-Go wins preferred status on Humana’s Medicare formularies appeared first on MassDevice.

from MassDevice http://bit.ly/2Asdqht